摘要
目的分析阿帕替尼所致高血压不良反应的特点及干预措施。方法收集2016年1月-2018年3月医院应用阿帕替尼治疗的晚期肿瘤住院患者102例,分析阿帕替尼所致高血压不良反应的临床特点、干预措施及转归。结果 102例患者出现高血压不良反应49例,发生率为48. 0%(49/102)。其中1级高血压18例(36. 7%),2级高血压24例(49. 0%),3级高血压7例(14. 3%),1级、2级高血压发生率高于3级高血压,差异均有统计学意义(P <0. 05)。阿帕替尼剂量850 mg/d、750 mg/d、500 mg/d高血压发生率分别为60. 7%、56. 2%和33. 3%,3个剂量高血压发生率比较差异均有统计学意义(P <0. 05)。1级、2级高血压选用适宜的抗高血压药物治疗后血压均控制良好,无需停药; 3级高血压经抗高血压治疗后血压控制良好6例,减量继续用药; 1例停用阿帕替尼。结论阿帕替尼所致高血压大部分较轻,经对症降压处理可得到良好控制。
Objective To analyze the characteristics and interventions of adverse reactions caused by apatinib in hypertension. Methods 102 patients with advanced cancer hospitalized patients treated with apatinib in hospital from January 2016 to February 2018 were collected,the clinical characteristics,interventions and outcomes of adverse reactions to hypertension induced by apatinib were analyzed. Results Of the 102 patients,49 had hypertension,and the incidence of adverse reactions was 48. 0% (49/102). Among them,these included 18 patients(36. 7%) with grade 1 hypertension,24 patients (49. 0%) with grade 2 hypertension,and 7 patients(14. 3%) with grade 3 hypertension,the incidence of grade 1 and grade 2 hypertension were higher than that of grade 3 hypertension,and the differences were statistically significant(P <0. 05). The incidence of hypertension with apapitril doses of 850 mg/d,750 mg/d,and 500 mg/d was 60. 7%,56. 2%,and 33. 3%, respectively,the differences in the three doses were statistically significant(P <0. 05). Grade 1 and 2 hypertension were well controlled with appropriate antihypertensive drugs,no need to stop the drug;Grade 3 hypertension was treated with antihypertensive therapy,and blood pressure was well controlled in 6 cases,the dose was continued to be discontinued;1 case was discontinued with apapitinib. Conclusion Most of the hypertension caused by apatinib is mild,and it can be well controlled by symptomatic antihypertensive treatment.
作者
苏贻洲
金泰宇
吴红
杨辉
SU Yizhou;JIN Taiyu;WU Hong(Department of Pharmacy,The Second People's Hospital of Lianyungang,Jiangsu Province,Lianyungang 222023,China)
出处
《临床合理用药杂志》
2018年第34期13-14,共2页
Chinese Journal of Clinical Rational Drug Use
基金
江苏大学医学临床科技发展基金项目资助(No:JLY20160170)
关键词
阿帕替尼
不良反应
高血压
Apatinib
Hypertension
Adverse reaction
